40 Participants Needed

AZD4076 for Healthy Male Subjects

No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

This is a first-in-human (FIH) study designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of AZD4076 tetracosasodium in healthy male subjects at increasing single doses

Research Team

RG

Ronald Goldwater, MDCM, M.Sc, CPI

Principal Investigator

PAREXEL Early Phase Clinical Unit Baltimore

Eligibility Criteria

Healthy male participants aged 18-50, with a BMI of 18-30 kg/m2 and weighing between 50-100 kg. They must have good veins for blood draws, provide consent, not smoke or use nicotine in the past three months, avoid certain medications before the trial, and not donate plasma or significant amounts of blood recently.

Inclusion Criteria

I have signed and agreed to participate in genetic research.
Provision of signed and dated, written informed consent prior to any study specific procedures
I am a healthy man aged 18-50 with good veins for needle procedures.
See 1 more

Exclusion Criteria

Vulnerable subjects
Severe allergy/hypersensitivity or ongoing clinically significant allergy/hypersensitivity
Excessive intake of caffeine containing drinks or food
See 21 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive a single ascending dose of AZD4076 tetracosasodium or placebo

1 day
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

16 weeks
Multiple visits (in-person and virtual)

Treatment Details

Interventions

  • AZD4076
  • Placebo
Trial Overview The study is testing AZD4076 tetracosasodium's safety and how it's processed by the body at different doses compared to a placebo. It's a first-in-human study involving healthy men who will receive single increasing doses to assess tolerability.
Participant Groups
6Treatment groups
Experimental Treatment
Group I: Cohort 6Experimental Treatment2 Interventions
Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
Group II: Cohort 5Experimental Treatment2 Interventions
Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
Group III: Cohort 4Experimental Treatment2 Interventions
Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
Group IV: Cohort 3Experimental Treatment2 Interventions
Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
Group V: Cohort 2Experimental Treatment2 Interventions
Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
Group VI: Cohort 1Experimental Treatment2 Interventions
Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)

Find a Clinic Near You

Who Is Running the Clinical Trial?

AstraZeneca

Lead Sponsor

Trials
4,491
Recruited
290,540,000+

Sir Pascal Soriot

AstraZeneca

Chief Executive Officer since 2012

Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris

Dr. Cristian Massacesi

AstraZeneca

Chief Medical Officer since 2021

MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology

Pascal Soriot

AstraZeneca

Chief Executive Officer since 2012

Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris

Cristian Massacesi

AstraZeneca

Chief Medical Officer since 2021

MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security